INTRAVITREAL INJECTION OF THERAPEUTIC AGENTS
The DOI matches its Crossref record; 523 of the 536 references it cites were found in a registry or an index.
Abstract
In Brief Background: Intravitreal injection (IVI) with administration of various pharmacological agents is a mainstay of treatment in ophthalmology for endopthalmitis, viral retinitis, age-related macular degeneration, cystoid macular edema, diabetic retinopathy, uveitis, vascular occlusions, and retinal detachment. The indications and therapeutic agents are reviewed in this study. Methods: A search of the English, German, and Spanish language MEDLINE database was conducted. A total of 654 references spanning the period through early 2008 were individually evaluated. Results: The advantage of the IVI technique is the ability to maximize intraocular levels of medications and to avoid the toxicities associated with systemic treatment. Intravitreal injection has been used to deliver several types of pharmacological agents into the vitreous cavity: antiinfective and antiinflammatory medications, immunomodulators, anticancer agents, gas, antivascular endothelial growth factor, and several others. The goal of this review is to provide a detailed description of the properties of numerous therapeutic agents that can be delivered through IVI, potential complications of the technique, and recommendations to avoid side effects. Conclusion: The IVI technique is a valuable tool that can be tailored to the disease process of interest based on the pharmacological agent selected. This review provides the reader with a comprehensive summary of the IVI technique and its multitude of uses. Intravitreal injection has been used to deliver numerous pharmacological agents into the vitreous cavity: antiinfective and antiinflammatory medications, immunomodulators, antineoplastic agents, gas, antivascular endothelial growth factor, and others. In this review, we describe the properties of many intravitreal therapeutic agents, the technique of intravitreal injection, complications, recommendations to avoid side effects, and future trends.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although rates of intraocular inflammation related to intravitreal injection remain relatively low, the overall burden on patients remains a key concern with millions of injections performed every year [85].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [85]
Citations
Cites
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Promotion of microtubule assembly in vitro by taxol
SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979) · Nature · doi:10.1038/277665a0 · Cited by 3,600
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Virus interference. I. the interferon
Isaacs, A., & Lindenmann, J. (1957) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1957.0048 · Cited by 3,451
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Effects of cytochalasin and phalloidin on actin.
Cooper, J. A. (1987) · The Journal of cell biology · doi:10.1083/jcb.105.4.1473 · Cited by 2,009
Guba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S., Anthuber, M., et al. (2002) · Nature Medicine · doi:10.1038/nm0202-128 · Cited by 1,739
The tor pathway: a target for cancer therapy
Bjornsti, M.-A., & Houghton, P. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1362 · Cited by 1,314
Research works printed but not linked: 9
- Komoto, 1912, Ueber Glaskorperwaschung bei unheilbarer Glaskorperblutung., KIin Monatsbl Augenheilkd, 50, 265
- Lowenstein, 1912, Uber Glaskorperersatz: 1.Teil: Experimentelle Untersuchungen., Albrecht von Graefes Arch Ophthalmol, 80, 500
- Zirm, 1925, Ein Beitrag zur Glaskorperabsaugung., Klin Monatsbl Augenheilkd, 75, 730
- Kucers, 1979, The Use of Antibiotics: A Comprehensive Review with Clinical Emphasis. 3rd ed.
- Smith, 2001, Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease., Arthritis Rheum, 45, 252, 10.1002/1529-0131(200106)45:3<252::aid-art257>3.0.co;2-5 · doi:10.1002/1529-0131(200106)45:3<252::aid-art257>3.0.co;2-5
- Rosenfeld, 2006, Ranibizumab: phase III clinical trial results., Ophthalmol Clin North Am, 19, 361
- Case, 1985, Clearance of intravitreal 3H-fluorouracil., Ophthalmic Surg, 16, 378
- Pillat, 1956, The aging of the retina., Trans Am Acad Ophthalmol Otolaryngol, 60, 206
- Dominguez, 1985, Cirugia precoz y ambulatoria del desprendimento de retina. (Spanish)., Arch Soc Esp Oftalmol, 48, 47
Cited by
Ocular drug delivery: present innovations and future challenges
Gote, V., Sikder, S., Sicotte, J., & Pal, D. (2019) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.256933 · Cited by 441
“Novel ocular drug-delivery technologies such as nanoformulations, implants, and other ocular devices allow enhanced drug residence time at the target tissue along with improvements in pharmacological response (Peyman et al., 2009).”
BackgroundDrug delivery to the posterior segment of the eye
Thrimawithana, T. R., Young, S., Bunt, C. R., Green, C., & Alany, R. G. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2010.12.004 · Cited by 335
Suprachoroidal drug delivery to the back of the eye using hollow microneedles
Patel, S. R., Lin, A. S. P., Edelhauser, H. F., & Prausnitz, M. R. (2011) · Pharmaceutical Research · doi:10.1007/s11095-010-0271-y · Cited by 330
2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations
Grzybowski, A., Told, R., Sacu, S., Bandello, F., Moisseiev, E., Loewenstein, A., Schmidt-Erfurth, U., & on behalf of the Euretina Board (2018) · Ophthalmologica · doi:10.1159/000486145 · Cited by 297
Complications of intravitreal injections
Sampat, K. M., & Garg, S. J. (2010) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e328338679a · Cited by 287
Metadata
- Authors
- PEYMAN, G. A., LAD, E. M., & MOSHFEGHI, D. M.
- Affiliations
- University of Arizona (US)
- Stanford University (US)
- Corresponding author
- PEYMAN, GHOLAM A.
- Venue
- Retina
- Published
- 2009-07
- Volume
- 29
- Issue
- 7
- Pages
- 875-912
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W2090780299
- Cited by
- 255
- References
- 536
- Citations by year
- 2026: 11 · 2025: 12 · 2024: 24 · 2023: 15 · 2022: 12 · 2021: 11 · 2020: 15 · 2019: 15 · 2018: 11 · 2017: 19 · 2016: 24 · 2015: 16 · 2014: 18 · 2013: 11 · 2012: 20
- FWCI
- 2.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Retina (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Keywords
- intravitreal injection, endophthalmitis, viral retinitis, age-related macular degeneration, cystoid macular edema, diabetic retinopathy, uveitis, retinal detachment, VEGF inhibitors, anti-inflammatory agents, immunomodulators, anticancer agents, gas tamponade, injection complications
- MeSH terms
- Drug Therapy, Humans, Injections, Vitreous Body
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: INTRAVITREAL INJECTION OF THERAPEUTIC AGENTS. https://app.cochat.ai/papers/10.1097/iae.0b013e3181a94f01
- The paper
- PEYMAN, G. A., LAD, E. M., & MOSHFEGHI, D. M. (2009). INTRAVITREAL INJECTION OF THERAPEUTIC AGENTS. Retina. https://doi.org/10.1097/iae.0b013e3181a94f01
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.